Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results
- PMID: 11600614
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results
Comment on
-
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.J Clin Oncol. 2001 Mar 15;19(6):1734-42. doi: 10.1200/JCO.2001.19.6.1734. J Clin Oncol. 2001. PMID: 11251004
Similar articles
-
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33338442 Clinical Trial.
-
Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.Digestion. 2016;93(3):229-33. doi: 10.1159/000445187. Epub 2016 Apr 19. Digestion. 2016. PMID: 27089254
-
Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma.Acta Oncol. 2014 Oct;53(10):1448-50. doi: 10.3109/0284186X.2014.926026. Epub 2014 Jun 16. Acta Oncol. 2014. PMID: 24930389 No abstract available.
-
[Chemotherapy in gallbladder carcinoma].Presse Med. 2010 Dec;39(12):1238-45. doi: 10.1016/j.lpm.2010.09.002. Epub 2010 Nov 11. Presse Med. 2010. PMID: 21074352 Review. French.
-
[Systemic chemotherapy with gemcitabine for advanced biliary tract carcinoma].Nihon Rinsho. 2006 Jan;64 Suppl 1:534-8. Nihon Rinsho. 2006. PMID: 16457320 Review. Japanese. No abstract available.
Cited by
-
Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway.Cancer Manag Res. 2020 May 19;12:3579-3587. doi: 10.2147/CMAR.S243660. eCollection 2020. Cancer Manag Res. 2020. PMID: 32547195 Free PMC article.
-
Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations.Mol Clin Oncol. 2018 Mar;8(3):421-428. doi: 10.3892/mco.2018.1550. Epub 2018 Jan 10. Mol Clin Oncol. 2018. PMID: 29456848 Free PMC article.
-
Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer.Cancer Med. 2016 Sep;5(9):2190-7. doi: 10.1002/cam4.782. Epub 2016 Jul 23. Cancer Med. 2016. PMID: 27449070 Free PMC article. Review.
-
The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.J Hematol Oncol. 2015 Apr 29;8:43. doi: 10.1186/s13045-015-0140-6. J Hematol Oncol. 2015. PMID: 25925741 Free PMC article.
-
Overexpression of deubiquitinating enzyme USP28 promoted non-small cell lung cancer growth.J Cell Mol Med. 2015 Apr;19(4):799-805. doi: 10.1111/jcmm.12426. Epub 2015 Feb 5. J Cell Mol Med. 2015. PMID: 25656529 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical